Pure Global
NCT06035679

Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

Prospective, Single-center, Observational Clinical Study of Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
Youzhi Zhu·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Breast Cancer Female
Drug/Device/Intervention
Pyrotinib and Trastuzumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Youzhi Zhu
Funder
First Affiliated Hospital of Fujian Medical University
Timeline & enrollment
Phase
N/A
Start date
Sep 20, 2023
End date
Nov 30, 2026
Enrollment
30 participants
Primary outcome

tpCR

Summary

This study is a prospective, single-center, observational clinical study, The objection was
 to observe the treatment of pyrotinib combined with trastuzumab and neoadjuvant chemotherapy
 Efficacy of Stage II-III breast cancer and observation of the efficacy of step-down
 neoadjuvant therapy for HER2-positive stage T1cN0M0 breast cancer.

ICD-10 classifications
Malignant neoplasm: Breast, unspecifiedMalignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedPersonal history of malignant neoplasm of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06035679
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06035679 through Pure Global AI's free database. This phase not specified trial is sponsored by Youzhi Zhu and is currently Not yet recruiting. The study focuses on Breast Cancer Female. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.